Sugi Predict

Sugi Predict / Compounds / SCHEMBL24374441

SCHEMBL24374441

SCHEMBL24374441

CCN1CCN(Cc2ccc(Nc3nc4c(C)c(Oc5ccnc(NC(C)=O)c5)ccc4[nH]3)cc2C(F)(F)F)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 7/20 0.54
▸ MKNK2 Q9HBH9 6/20 0.54
▸ BCR P11274 5/20 0.54
▸ MKNK1 Q9BUB5 5/20 0.54
▸ MAPK14 Q16539 8/20 0.52
▸ MAP3K20 Q9NYL2 4/20 0.52
▸ MAP3K7 O43318 6/20 0.49
▸ MAP4K2 Q12851 6/20 0.49
▸ RET P07949 2/20 0.48
▸ CYP3A4 P08684 1/20 0.47
▸ FES P07332 4/20 0.46
▸ FER P16591 4/20 0.46
▸ MAP4K4 O95819 2/20 0.46
▸ RAF1 P04049 2/20 0.46
▸ LYN P07948 2/20 0.46
▸ SRC P12931 2/20 0.46
▸ EPHA2 P29317 2/20 0.46
▸ EPHB2 P29323 2/20 0.46
▸ FLT3 P36888 2/20 0.46
▸ CSK P41240 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24374434 0.89 ABL1 (0.54) ABL1MKNK2BCRMKNK1MAPK14
SCHEMBL23795614 0.85 MKNK2 (0.54) ABL1MKNK2BCRMKNK1MAPK14
SCHEMBL24374458 0.83 ABL1 (0.55) ABL1MKNK2BCRMKNK1MAPK14
SCHEMBL23795595 0.82 ABL1 (0.54) ABL1MKNK2BCRMKNK1MAPK14
SCHEMBL25592393 0.82 MKNK2 (0.48) ABL1MKNK2BCRMKNK1MAPK14
SCHEMBL23205749 0.81 ABL1 (0.51) ABL1MKNK2BCRMKNK1MAPK14
SCHEMBL23205899 0.79 ABL1 (0.52) ABL1MKNK2BCRMKNK1MAPK14
SCHEMBL25592834 0.79 MKNK2 (0.58) ABL1MKNK2BCRMKNK1MAPK14
SCHEMBL23205750 0.78 ABL1 (0.53) ABL1MKNK2BCRMKNK1MAPK14
SCHEMBL24007134 0.78 ABL1 (0.60) ABL1MKNK2BCRMKNK1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183204-A9 BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-15 — — US disclosed
US-20230183204-A9 BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-15 — — US disclosed
US-20220127246-A1 BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127246-A1 BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF JAK1, JAK2, JAK3 ABL1 18/4885MKNK2 585/4885BCR 1084/4885
US-20230183204-A9 BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF JAK1, JAK2, JAK3 ABL1 18/4885MKNK2 585/4885BCR 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.